RATIONALE: Mechanical ventilation with O₂-rich gas (MV-O₂) offers life-saving treatment for respiratory failure, but also promotes lung injury. We previously reported that MV-O2 of newborn mice increased lung elastase activity, causing elastin degradation and redistribution of elastic fibers from septal tips to alveolar walls. These changes were associated with transforming growth factor (TGF)-β activation and increased apoptosis leading to defective alveolarization and lung growth arrest, as seen in neonatal chronic lung disease. OBJECTIVES: To determine if intratracheal treatment of newborn mice with the serine elastase inhibitor elafin would prevent MV-O₂-induced lung elastin degradation and the ensuing cascade of events causing lung growth arrest. METHODS: Five-day-old mice were treated via tracheotomy with recombinant human elafin or vehicle (lactated-Ringer solution), followed by MV with 40% O₂ for 8-24 hours; control animals breathed 40% O₂ without MV. At study's end, lungs were harvested to assess key variables noted below. MEASUREMENTS AND MAIN RESULTS: MV-O₂ of vehicle-treated pups increased lung elastase and matrix metalloproteinase-9 activity when compared with unventilated control animals, causing elastin degradation (urine desmosine doubled), TGF-β activation (pSmad-2 tripled), and apoptosis (cleaved-caspase-3 increased 10-fold). Quantitative lung histology showed larger and fewer alveoli, greater inflammation, and scattered elastic fibers. Elafin blocked these MV-O₂-induced changes. CONCLUSIONS: Intratracheal elafin, by blocking lung protease activity, prevented MV-O₂-induced elastin degradation, TGF-β activation, apoptosis, and dispersion of matrix elastin, and attenuated lung structural abnormalities noted in vehicle-treated mice after 24 hours of MV-O₂. These findings suggest that elastin breakdown contributes to defective lung growth in response to MV-O₂ and might be targeted therapeutically to prevent MV-O₂-induced lung injury.
RATIONALE: Mechanical ventilation with O₂-rich gas (MV-O₂) offers life-saving treatment for respiratory failure, but also promotes lung injury. We previously reported that MV-O2 of newborn mice increased lung elastase activity, causing elastin degradation and redistribution of elastic fibers from septal tips to alveolar walls. These changes were associated with transforming growth factor (TGF)-β activation and increased apoptosis leading to defective alveolarization and lung growth arrest, as seen in neonatal chronic lung disease. OBJECTIVES: To determine if intratracheal treatment of newborn mice with the serine elastase inhibitor elafin would prevent MV-O₂-induced lung elastin degradation and the ensuing cascade of events causing lung growth arrest. METHODS: Five-day-old mice were treated via tracheotomy with recombinant humanelafin or vehicle (lactated-Ringer solution), followed by MV with 40% O₂ for 8-24 hours; control animals breathed 40% O₂ without MV. At study's end, lungs were harvested to assess key variables noted below. MEASUREMENTS AND MAIN RESULTS:MV-O₂ of vehicle-treated pups increased lung elastase and matrix metalloproteinase-9 activity when compared with unventilated control animals, causing elastin degradation (urine desmosine doubled), TGF-β activation (pSmad-2 tripled), and apoptosis (cleaved-caspase-3 increased 10-fold). Quantitative lung histology showed larger and fewer alveoli, greater inflammation, and scattered elastic fibers. Elafin blocked these MV-O₂-induced changes. CONCLUSIONS: Intratracheal elafin, by blocking lung protease activity, prevented MV-O₂-induced elastin degradation, TGF-β activation, apoptosis, and dispersion of matrix elastin, and attenuated lung structural abnormalities noted in vehicle-treated mice after 24 hours of MV-O₂. These findings suggest that elastin breakdown contributes to defective lung growth in response to MV-O₂ and might be targeted therapeutically to prevent MV-O₂-induced lung injury.
Authors: A Murat Kaynar; A McGarry Houghton; Esther H Lum; Bruce R Pitt; Steven D Shapiro Journal: Am J Respir Cell Mol Biol Date: 2008-02-14 Impact factor: 6.914
Authors: T A Merritt; C G Cochrane; K Holcomb; B Bohl; M Hallman; D Strayer; D K Edwards; L Gluck Journal: J Clin Invest Date: 1983-08 Impact factor: 14.808
Authors: Lucia M Mokres; Kakoli Parai; Anne Hilgendorff; Robert Ertsey; Cristina M Alvira; Marlene Rabinovitch; Richard D Bland Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-10-23 Impact factor: 5.464
Authors: Branka Dabovic; Yan Chen; Jiwon Choi; Melinda Vassallo; Harry C Dietz; Francesco Ramirez; Harald von Melchner; Elaine C Davis; Daniel B Rifkin Journal: J Cell Physiol Date: 2009-04 Impact factor: 6.384
Authors: Richard D Bland; Robert Ertsey; Lucia M Mokres; Liwen Xu; Berit E Jacobson; Shu Jiang; Cristina M Alvira; Marlene Rabinovitch; Eric S Shinwell; Anjali Dixit Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-10-12 Impact factor: 5.464
Authors: Paula Tejera; Zhaoxi Wang; Rihong Zhai; Li Su; Chau-Chyun Sheu; Deanne M Taylor; Feng Chen; Michelle N Gong; B Taylor Thompson; David C Christiani Journal: Am J Respir Cell Mol Biol Date: 2009-02-27 Impact factor: 6.914
Authors: Marla R Wolfson; Jichuan Wu; Terrence L Hubert; Timothy J Gregory; Jan Mazela; Thomas H Shaffer Journal: Pediatr Res Date: 2012-07-20 Impact factor: 3.756
Authors: Darcy E Wagner; Wellington V Cardoso; Sarah E Gilpin; Susan Majka; Harald Ott; Scott H Randell; Bernard Thébaud; Thomas Waddell; Daniel J Weiss Journal: Ann Am Thorac Soc Date: 2016-08
Authors: Harald Ehrhardt; Tina Pritzke; Prajakta Oak; Melina Kossert; Luisa Biebach; Kai Förster; Markus Koschlig; Cristina M Alvira; Anne Hilgendorff Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-03-25 Impact factor: 5.464